Detailed Explanation
Exenatide is a 39-amino-acid peptide originally discovered in the saliva of the Gila monster lizard (Heloderma suspectum) by John Eng at the Bronx VA Medical Center in 1992. The natural peptide, called exendin-4, shares 53% sequence identity with human GLP-1 but critically lacks the DPP-IV cleavage site that destroys native GLP-1 in minutes. This natural protease resistance gives exenatide a half-life of approximately 2.4 hours — long enough for twice-daily injection as a diabetes drug.
Exenatide was approved by the FDA in 2005 as Byetta (twice-daily injection) and later as Bydureon (once-weekly extended-release microsphere formulation). As a GLP-1 receptor agonist, it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. It was the first-in-class drug that proved the GLP-1 pathway could be therapeutically exploited for type 2 diabetes and weight management.
Exenatide's discovery from reptile venom is one of the most celebrated examples of biodiscovery — finding drugs in nature's chemical library. It opened the door for the entire GLP-1 receptor agonist class, leading to liraglutide (2010), semaglutide (2017), and tirzepatide (2022). While exenatide has been largely superseded by once-weekly competitors with greater weight loss efficacy, it remains historically significant as the drug that launched the GLP-1 revolution.
Key Facts
- 39 amino acids, derived from Gila monster (Heloderma suspectum) venom
- Discovered by John Eng, 1992; FDA approved 2005
- 53% sequence identity with human GLP-1
- Naturally resistant to DPP-IV (half-life ~2.4 hours vs. ~2 min for GLP-1)
- Brands: Byetta (twice daily), Bydureon (weekly extended-release)
- First GLP-1 receptor agonist — launched the entire drug class
Part of the PeptideBond.com education network
Educational Disclaimer
PeptideDefinition.com provides educational content about peptide science. Not medical advice. Consult a licensed healthcare provider for medical decisions.